Inovio Pharmaceuticals (INO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 May, 2026Opening remarks and agenda
Meeting convened virtually with all directors and key officers present, confirming quorum and opening business.
Agenda included election of directors, ratification of auditors, executive compensation, and incentive plan amendment.
Board and executive committee updates
Eight directors nominated and elected to serve until the next annual meeting.
Shareholder proposals
Proposals included election of directors, ratification of Ernst & Young LLP as auditors, advisory approval of executive compensation, and amendment of the 2023 Omnibus Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Inovio Pharmaceuticals
- INO-3107 BLA delayed to mid-2025; Q2 net loss $32.2M, cash runway into Q3 2025.INO
Q2 20249 Jul 2026 - INO-3107 BLA submission on track, net loss narrows, and cash runway extends into 2026.INOQ4 20249 Jul 2026
- INO-3107 BLA under FDA review; FY2025 net loss narrows, cash runway into Q4 2026.INOQ4 20259 Jul 2026
- Net loss narrowed and cash runway extends into Q1 2026 as INO-3107 advances toward BLA submission.INOQ1 20258 Jul 2026
- INO-3107 showed 81% efficacy in reducing surgeries, with cash runway into Q3 2025.INOQ3 20248 Jul 2026
- High risk from clinical, regulatory, and financial uncertainties; forward-looking statements may not be accurate.INORegistration filing2 Jul 2026
- INO-3107 shows strong efficacy in RRP, with regulatory review and commercial launch plans advancing.INOJefferies Global Healthcare Conference 20264 Jun 2026
- INO-3107 BLA under FDA review; Q1 net loss $19.7M; cash runway into Q1 2027.INOQ1 202619 May 2026
- INO-3107 for RRP shows strong efficacy and durability, with BLA submission targeted for mid-2025.INOCorporate presentation16 Apr 2026